Champions Oncology (CSBR) Gains from Investment Securities (2018 - 2026)
Champions Oncology (CSBR) recorded quarterly Gains from Investment Securities of -$89000.0 in Q1 2026, down 345.0% quarter-over-quarter from -$20000.0 in Q3 2025.
Champions Oncology (CSBR) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Champions Oncology's Gains from Investment Securities history runs 8 years deep, the most recent figure standing at -$89000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$89000.0; the TTM figure through Jan 2026 stood at -$402000.0 (down 1575.0% YoY), while the FY2025 annual figure was -$293000.0, down 300.68% from the prior year.
- Gains from Investment Securities was -$89000.0 for Q1 2026 at Champions Oncology, down from -$20000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $96000.0 in Q1 2024 to a low of -$293000.0 in Q2 2025.
- Historically, Gains from Investment Securities has averaged -$32000.0 across 4 years, with a median of -$22000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 150.0% in 2024, then sank 1120.83% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at $74000.0 in 2023, then tumbled by 150.0% to -$37000.0 in 2024, then jumped by 45.95% to -$20000.0 in 2025, then plunged by 345.0% to -$89000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$89000.0 (Q1 2026), -$20000.0 (Q3 2025), and -$293000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Champions Oncology | 82.77 Mn | 75.76 Mn | 13.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -89,000.00 |
| Jan 31, 2026 | -89,000.00 |
| Jul 31, 2025 | -20,000.00 |
| Jul 31, 2025 | -20,000.00 |
| Apr 30, 2025 | -293,000.00 |
| Apr 30, 2025 | -293,000.00 |
| Oct 31, 2024 | -37,000.00 |
| Oct 31, 2024 | -37,000.00 |
| Jul 31, 2024 | 37,000.00 |
| Jul 31, 2024 | 37,000.00 |
| Apr 30, 2024 | -24,000.00 |
| Apr 30, 2024 | -24,000.00 |
| Jan 31, 2024 | 96,000.00 |
| Jan 31, 2024 | 96,000.00 |
| Oct 31, 2023 | 74,000.00 |
| Oct 31, 2023 | 74,000.00 |
| Jul 31, 2021 | 4,000.00 |
| Jul 31, 2021 | 4,000.00 |
| Apr 30, 2021 | -173,000.00 |
| Apr 30, 2021 | -173,000.00 |